<DOC>
	<DOCNO>NCT01649245</DOCNO>
	<brief_summary>It multi-center study efficacy new Pegylated Hansenula-derived recombinant interferon α 2a ( Reiferon Retard® 160 µg weekly combination ribavirin treatment Egyptian patient chronic hepatitis C 48 week . hepatitis C virus ( HCV ) viral load assess therapy week 12 , 24 end treatment , well 24 week therapy complete .</brief_summary>
	<brief_title>Hansenula-derived Pegylated Interferon Treatment Patients With Chronic Hepatitis C</brief_title>
	<detailed_description>Multicenter , Phase IV , open label , non-randomized trial ass Efficacy Hansenula-derived recombinant pegylated interferon α 2a ( Reiferon Retard® treatment naïve chronic hepatitis c virus Egyptian patient . Each participant subject thorough history taking , complete clinical examination , Biochemical laboratory hematological test , U/S image well histologic assessment liver disease stage severity ensure his/her eligibility enrol study accord predetermine inclusion exclusion criterion . Eligible subject treat Reiferon Retard® 160 µg weekly subcutaneous injection 48 week treatment plus weight-based Ribavirin orally ( 1200 mg/kg daily &gt; 75 Kg 1000mg/Kg daily ≤ 75 kg divide dos ) . HCV RNA assess week 12 initiation therapy identify Early Virologic Response ( EVR ) , week 24 identify breakthrough viremia , week 48 identify End treatment Response ( ETR ) , week 72 identify Sustained Virologic Response ( SVR ) . All subject follow study describe table ( Section 4 Study Design ) .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>1 . Age &gt; 18 &lt; 60 . 2 . BMI ≤ 30 3 . Liver biopsy show chronic hepatitis significant fibrosis ( F2 F3 use Metavir score system ) regardless aminotransferase elevation . 4 . F1 stage ( Metavir score system ) elevate aminotransferase . 5 . Compensated liver disease ; serum bilirubin &lt; 1.5 mg/dl , INR 1.5 , serum albumin ≥ 3.5 g/dl , platelet count ≥ 1000 cmm , evidence hepatic decompensation ( hepatic encephalopathy ascites ) . 6 . Acceptable hematological biochemical index ( hemoglobin ≥ 11g/dl ; total leukocytic count ≥ 3000/cmm , absolute neutrophil count ≥ 1500/cmm serum creatinine &lt; 1.97 mg/dl . 7 . Willing treat adhere treatment requirement . 1 . Major uncontrolled depressive illness . 2 . Solid organ transplantation . 3 . Autoimmune condition , know exacerbate peginterferon ribavirin . 4 . Untreated thyroid disease . 5 . Pregnant unwilling comply adequate contraception . 6 . Severe concurrent medical disease , severe hypertension , heart failure , significant coronary artery disease , poorly control diabetes ( HbA1C &gt; 8.5 % ) , chronic obstructive pulmonary disease . 7 . Known hypersensitivity drug use treat HCV .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Chronic hepatitis C</keyword>
	<keyword>Egyptian patient</keyword>
	<keyword>pegylated interferon</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Reiferon retard</keyword>
</DOC>